How to Obtain AMA
PRA Category 1
Credit(s)™
- Listen to the CME audio discussion.
- Take the CME posttest.
- Login to your account.
- Complete the registration / evaluation form.
- Print your personalized
CME certificate.
Rheumatology
Online CME
Survey
|
|
|
|
|
| |
| Release Date: October 30, 2008 |
Expiration Date: October 30, 2009 |
Technical Requirements
(will appear in new window)
| Estimated Time of Completion |
1 hour |
| Description / Overview |
The purpose of this activity is to examine the risk of malignancy in patients with rheumatoid arthritis (RA), clarify the association of malignancy and treatment for RA, and determine treatment options for a patient with RA who has a history of lymphoma. |
| Objectives |
At the conclusion of this activity, the participant will be able to:
- Explain the relative risks for specific malignancies in patients with RA.
- Review safety data concerning malignancy and the use of disease-modifying antirheumatic drugs (DMARDs) or biologics in patients with RA.
- Discuss treatment options for a patient with RA who has a history of lymphoma.
|
| Target Audience |
This activity is directed to rheumatologists and primary care physicians who treat patients with RA. |
| Accreditation |
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2. |
| Activity Director |
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio |
| Author / Faculty |
Kevin M. Latinis, MD, PhD |
| Faculty Disclosure |
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO |
| |
Consulting: |
Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc. |
| |
| |
Teaching
and Speaking: |
Genentech, Inc. |
| |
| Kevin M. Latinis, MD, PhD |
| |
Consulting: |
Genentech, Inc. |
| |
| |
Teaching
and Speaking: |
Genentech, Inc. |
|
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:
Bristol – Myers Squibb Company, Genentech/Biogen Idec
Wyeth Pharmaceuticals
This CME activity was produced by
The Cleveland Clinic Foundation
Center for Continuing Education and DIME.
Contact Information | Privacy Policy | Disclaimer
Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.
|
